• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To McKesson (MCK) Portfolio Shift Toward Oncology And Medical-Surgical Spin-Off

    Simply Wall St·09/03/2026 00:47:22
    語音播報
    • In recent months, McKesson completed the sale of its Canadian operations, exited Norway, and announced plans to spin off its Medical-Surgical unit while expanding its U.S. Oncology Network through acquisitions of PRISM Vision and Core Ventures.
    • This reshaping of the portfolio toward higher-margin oncology and specialty services, alongside raised fiscal 2027 guidance after stronger first-quarter operating profit, signals a clearer focus on businesses seen as more profitable and resilient.
    • Next, we'll examine how McKesson's planned Medical-Surgical spin-off could reshape its investment narrative and long-term business mix.

    AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    McKesson Investment Narrative Recap

    To own McKesson, you need to believe its shift toward oncology, specialty services, and higher-value solutions can offset pressure on traditional drug distribution. The recent portfolio reshaping does not materially change the biggest near term catalyst, which remains execution on this transition, or the key risk from regulatory and pricing pressure on pharma distribution margins.

    The planned spin off of the Medical Surgical unit is the most relevant move here, because it directly affects how much of McKesson’s earnings will come from higher margin oncology and specialty businesses versus lower margin distribution. How cleanly and efficiently this separation is executed will likely influence how investors view the quality and resilience of McKesson’s future earnings mix.

    Yet investors also need to weigh the possibility that increasing regulatory scrutiny on drug pricing could...

    Read the full narrative on McKesson (it's free!)

    McKesson's narrative projects $502.2 billion revenue and $6.3 billion earnings by 2029. This requires 6.9% yearly revenue growth and about a $1.7 billion earnings increase from $4.6 billion today.

    Uncover how McKesson's forecasts yield a $980.80 fair value, a 6% upside to its current price.

    Exploring Other Perspectives

    MCK 1-Year Stock Price Chart
    MCK 1-Year Stock Price Chart

    Three fair value estimates from the Simply Wall St Community span roughly US$981 to US$1,675 per share, reflecting very different expectations for McKesson’s potential. Against this wide range of views, the company’s push into higher margin oncology and specialty services raises important questions about how its evolving business mix could affect future earnings resilience, which readers may want to compare with these community assumptions.

    Explore 3 other fair value estimates on McKesson - why the stock might be worth as much as 81% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.